DEC 2013

Russel J Howard Takes out Overrall Winner of Advance Global Australina Awards 2013

Russell Howard was the overall Advance Global Australian Award winner, selected from the category winners and announced at the event. The Advance Global Australian Awards celebrate the achievements of Australians living overseas who exhibit remarkable talent, ambition and exceptional vision. They are the only awards to recognize the important contributions of the more than one million Australians living abroad. The Awards Forum and Ceremony took on 21 March 2013, at the Museum of Contemporary Art, Sydney, Australia.

DEC 2012

NeuClone invited to Present at IBC Asia Conference: Cell Line Development & Engineering Asia 2012

NeuClone is invited to present  at the Cell Line Development & Engineering Asia Conference Feb 21-23 in Shanghai, China.  The conference brings together experts and top scientists from biopharmas, biotechs, CMOs and research institutes to collectively collaborate and provide solutions to  the biggest challenges in the industry today.

NOV 2012

Dr Nigel Jenkins joins NeuClone team

Dr Nigel Jenkins, world renowned scientist in the area of process development and post translational modification of proteins, joins us from his previous position held at the National Institute for Bioprocessing Research & Teaching in Dublin, Ireland. Nigel is leading the process development team at NeuClone. Read more.

OCT 2011

NeuClone to expand laboratory facilities at the ATP

NeuClone begins construction on extending its existing facilities at the Australian Technology Park, Sydney. New facilities include additional clean rooms and office space.

Lupin Announces Licensing Arrangement with NeuClone

(Reuters). Mumbai / Sydney, 1 June, 2011: Pharma Major, Lupin Limited today announced a strategic licensing agreement with Sydney based private specialty life science company NeuClone Pty Ltd for their cell line technology. Under the terms of the agreement, NeuClone will provide an exclusive proprietary mammalian CHO cell line which will express a specific recombinant protein of interest in Oncology to its partner. The agreement will also entail the Lupin Biological Research Program scientific research staff working with NeuClone Teams at their facility as a part of the overall technology transfer arrangements as specified within the agreement. Commenting on the agreement Dr. Cyrus Karkaria, President, Lupin Limited and Head of the Lupin Biological Research Program said "The multi-billion dollar opportunity with blockbuster Biologics going off patent in the next 5-8 years is something that Lupin is pursuing aggressively. This exclusive licensing arrangement with NeuClone is a part of that strategy and would enable us to capitalize on cutting edge technology to address the Biologicals Market. This agreement and such similar agreements, coupled with our own pipeline will go a long way in helping us address the impending opportunity and develop a substantial differentiated biological pipeline." NeuClone CEO, Dr Noelle Sunstrom said "This is an exciting time for NeuClone and our stakeholders as our investment in mammalian CHO cell lines is commercialised. In particular, we are enthusiastic about further developing the relationship with Lupin, an important global generic manufacturer."

Collaboration with the University of Western Sydney

NeuClone is pleased to announce a collaboration with the University of Western Sydney, Deparment of Industrial Design for the development of innovative products in the field of mammalian cell culture technology. Driven by the commercial success of biopharmaceutical products, there is an increasing demand for novel mammalian cell culture systems for the rapid production of biotechnology derived therapeutics that require mammalian cell culturing processes. NeuClone has identified several opportunities for improving cell culture processes to accelerate upstream product development.

MAR 2011

Biosimilars Asia 2011

Dr Noelle Sunstrom to attend the Biosimilars Asia 2011 conference in Shanghai China on 23-26 May 2011 where she will chair the session on R&D strategies to gain approval and acceptance of biosimilars. Dr Sunstrom will also give a presentation on Engineering Mammalian Cell Lines for the Biosimilars Industry.